title: Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
authors.forename: Gerald
authors.initials: G
authors.lastname: Streit
authors.forename: Gaelle
authors.initials: G
authors.lastname: Lehuédé
authors.forename: Eric
authors.initials: E
authors.lastname: Toussirot
authors.forename: Agnès
authors.initials: A
authors.lastname: Aubin
authors.forename: Alain
authors.initials: A
authors.lastname: Petitjean
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001168:Arthritis / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D011241:Prednisone; D008727:Methotrexate